(S)-2-(4-fluorobenzyl)-6,7-dihydroxy-2,3,10,10a-tetrahydroimidazo[1,5-b]isoquinolin-1(5H)-one

ID: ALA5180147

Chembl Id: CHEMBL5180147

PubChem CID: 168273818

Max Phase: Preclinical

Molecular Formula: C18H17FN2O3

Molecular Weight: 328.34

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C1[C@@H]2Cc3c(ccc(O)c3O)CN2CN1Cc1ccc(F)cc1

Standard InChI:  InChI=1S/C18H17FN2O3/c19-13-4-1-11(2-5-13)8-21-10-20-9-12-3-6-16(22)17(23)14(12)7-15(20)18(21)24/h1-6,15,22-23H,7-10H2/t15-/m0/s1

Standard InChI Key:  DIKUFJHORKLHKE-HNNXBMFYSA-N

Alternative Forms

  1. Parent:

    ALA5180147

    ---

Associated Targets(Human)

TRPV1 Tclin Vanilloid receptor (8273 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Trpm8 Transient receptor potential cation channel subfamily M member 8 (889 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 328.34Molecular Weight (Monoisotopic): 328.1223AlogP: 1.96#Rotatable Bonds: 2
Polar Surface Area: 64.01Molecular Species: NEUTRALHBA: 4HBD: 2
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 9.12CX Basic pKa: 2.98CX LogP: 2.48CX LogD: 2.48
Aromatic Rings: 2Heavy Atoms: 24QED Weighted: 0.83Np Likeness Score: -0.19

References

1. Di Sarno V, Giovannelli P, Medina-Peris A, Ciaglia T, Di Donato M, Musella S, Lauro G, Vestuto V, Smaldone G, Di Matteo F, Bifulco G, Castoria G, Migliaccio A, Fernandez-Carvajal A, Campiglia P, Gomez-Monterrey I, Ostacolo C, Bertamino A..  (2022)  New TRPM8 blockers exert anticancer activity over castration-resistant prostate cancer models.,  238  [PMID:35598411] [10.1016/j.ejmech.2022.114435]

Source